Exploitation Strategies
A requirement of EU grant funding is the research results must be made available to achieve FP7 objectives, in this case Patient Safety.
Where possible the EU prefers commercial organizations to establish successful businesses, based on the value add of the research results, and preferably SMEs based in Europe.
In our case we describe this process of implementation to:
- improve patient safety and health care outcomes
- reduce relative health care costs
- create a successful business capable of providing the technology to global markets and make profits in the process
as “Exploitation”.
We intend taking a phased approach to exploitation which will take the shortest and lowest cost route to revenue, in that way achieving funding to support the subsequent phases. Each phase will stand alone as an independent business proposition whilst building toward our grand design.
Phase 1 Clinical Research Hub
1. We’ll duplicate our existing infrastructure – hardware and software – offering it to clinical researchers as a repository for their own research data. They’ll be able to use our tools to access and analyse their data, and share it with colleagues as appropriate.
2. We’ll provide both the monitor interface software and the bedside data capture software to users, to facilitate their data capture.
3. We’ll provide BANN software to enable collaborative research.
The facilities will be offered using the ‘Freemium” pricing model made popular in the Web 2.0 sector. Basic services will be provided free, with premium pricing for additional, more valuable services.
Phase 2 Open Source Software
We’ll offer a selection of the tools, including the BANN software as free, open source to the research community, both hospitals, universities and other research projects. We’ll retain control of the development of the source and provide packaging and maintenance support for organisations using the software in operational systems.
Phase 3 Contract Research
Using our tools and infrastructure we’ll provide services to research businesses data, based on experience developed in Avert-IT.
Phase 4 Hypopredict
This solution will comprise local systems for hospitals and a central hub. Local software will collect and analyse data, alerting clinicians to impending adverse events including but not limited to hypotension. In parallel the data will be transmitted to the central hub and used for further research. Prediction tools will be enhanced, analysis tools improved and clinical intelligence tools developed for evidence based medicine and clinical governance applications.
Phase 4 will be implemented in partnership with global vendors wanting to enter the healthcare sector. These have yet to be identified but Dell, Teradata, IBM, SAS, Microsoft, Accenture are examples of major suppliers with established businesses in health care business applications, and wishing to extend their reach into clinical systems.
